Overview
SCIENTIFIC SCORE
Possibly Effective
Based on 26 Researches
7.2
USERS' SCORE
Good
Based on 2 Reviews
8.5
Supplement Facts
Serving Size: 1 Softgel
Amount Per Serving
%DV
Calories
10
Total Fat
1 g
1%
Saturated Fat
0 g
0%
Trans Fat
0 g
**
Polyunsaturated Fat
0.5 g
**
Monounsaturated Fat
0 g
**
Cholesterol
10 mg
3%
Omega-3 Fish Oil
1000 mg
**
EPA (Eicosapentaenoic Acid)
180 mg
**
DHA (Docosahexaenoic Acid)
120 mg
**
Top Medical Research Studies
8
We aimed to understand how eicosapentaenoic acid (EPA) affects psoriasis, a skin condition known for causing redness, irritation, and thickened skin. By creating skin models that reflect both healthy and psoriatic conditions, we were able to assess the impact of EPA directly on lipid profiles—a key factor in skin health.
Our research revealed that in psoriatic skin models, there was a notable increase in certain fatty acids linked to inflammation, such as arachidonic acid (AA) and linoleic acid (LA). However, when we supplemented the media with EPA, we noticed a significant shift. The levels of beneficial omega-3 fatty acids, including EPA, docosahexaenoic acid (DHA), and docosapentaenoic acid (DPA), rose in both epidermal and dermal tissues.
More importantly, the addition of EPA helped to balance the production of lipid mediators in the skin. We observed increases in several anti-inflammatory molecules, such as prostaglandin E (PGE) and 12-hydroxyeicosapentaenoic acid (12-HEPE), indicating a move toward a more stable and healthier skin environment. These results suggest that EPA could play an important role in managing psoriasis by promoting a healthier lipid balance in the skin, potentially easing symptoms and encouraging skin healing.
Our research revealed that in psoriatic skin models, there was a notable increase in certain fatty acids linked to inflammation, such as arachidonic acid (AA) and linoleic acid (LA). However, when we supplemented the media with EPA, we noticed a significant shift. The levels of beneficial omega-3 fatty acids, including EPA, docosahexaenoic acid (DHA), and docosapentaenoic acid (DPA), rose in both epidermal and dermal tissues.
More importantly, the addition of EPA helped to balance the production of lipid mediators in the skin. We observed increases in several anti-inflammatory molecules, such as prostaglandin E (PGE) and 12-hydroxyeicosapentaenoic acid (12-HEPE), indicating a move toward a more stable and healthier skin environment. These results suggest that EPA could play an important role in managing psoriasis by promoting a healthier lipid balance in the skin, potentially easing symptoms and encouraging skin healing.
Read More
9
Eicosapentaenoic acid benefits psoriasis
We assessed the effects of eicosapentaenoic acid (EPA), an omega-3 fatty acid, on psoriasis through intravenous administration in a series of studies. The investigation aimed to understand whether replacing arachidonic acid, which has pro-inflammatory properties, with EPA could be beneficial for patients suffering from psoriasis.
Participants received daily infusions of either an EPA-based lipid emulsion or a conventional n-6 lipid emulsion. Throughout the studies, we closely monitored the clinical progression of psoriasis, along with specific inflammatory markers in the blood.
Our findings were notable: the group receiving the n-3 fatty acid treatment showed a significantly higher response rate. We observed a remarkable tenfold increase in specific products derived from neutrophils, indicating enhanced benefits from EPA. Additionally, plasma levels of EPA rose swiftly within just a few days of treatment.
In summary, our research suggests that intravenous administration of n-3 fatty acids effectively reduces psoriasis symptoms, likely due to alterations in inflammatory processes. This rapid response contrasts sharply with slower improvements seen with oral supplementation of fatty acids.
Participants received daily infusions of either an EPA-based lipid emulsion or a conventional n-6 lipid emulsion. Throughout the studies, we closely monitored the clinical progression of psoriasis, along with specific inflammatory markers in the blood.
Our findings were notable: the group receiving the n-3 fatty acid treatment showed a significantly higher response rate. We observed a remarkable tenfold increase in specific products derived from neutrophils, indicating enhanced benefits from EPA. Additionally, plasma levels of EPA rose swiftly within just a few days of treatment.
In summary, our research suggests that intravenous administration of n-3 fatty acids effectively reduces psoriasis symptoms, likely due to alterations in inflammatory processes. This rapid response contrasts sharply with slower improvements seen with oral supplementation of fatty acids.
Read More
We explored the effectiveness of a specialized treatment regimen involving docosahexaenoic acid (DHA) as part of an n-3 fatty acid lipid infusion for patients suffering from acute guttate psoriasis. This study included twenty hospitalized individuals with significant skin involvement and was conducted in a randomized, double-blind, placebo-controlled manner to ensure reliable results.
Participants received either a daily infusion of the n-3 fatty acid emulsion, which contained DHA and eicosapentaenoic acid (EPA), or a conventional n-6 lipid emulsion lacking significant benefits from omega-3s. We recorded clinical changes over ten days, assessing factors such as skin redness, swelling, and peeling, along with patients' subjective feelings about their symptoms.
The results were telling: those receiving the n-3 infusion showed a remarkable improvement in their psoriasis symptoms—between 45% and 76%—within just ten days. In contrast, the n-6 group experienced only moderate improvement, around 16-25%. Furthermore, we noted significant changes in the patients' immune response. The n-3 group had an increased production of beneficial leukotriene products, while inflammatory markers decreased, suggesting a positive modulation of the body's inflammatory response by DHA and EPA.
Overall, our investigation highlights a potential rapid benefit of using n-3 fatty acids, particularly DHA, in treating acute psoriasis. This indicates a promising avenue for improving the lives of those affected by this challenging skin condition.
Participants received either a daily infusion of the n-3 fatty acid emulsion, which contained DHA and eicosapentaenoic acid (EPA), or a conventional n-6 lipid emulsion lacking significant benefits from omega-3s. We recorded clinical changes over ten days, assessing factors such as skin redness, swelling, and peeling, along with patients' subjective feelings about their symptoms.
The results were telling: those receiving the n-3 infusion showed a remarkable improvement in their psoriasis symptoms—between 45% and 76%—within just ten days. In contrast, the n-6 group experienced only moderate improvement, around 16-25%. Furthermore, we noted significant changes in the patients' immune response. The n-3 group had an increased production of beneficial leukotriene products, while inflammatory markers decreased, suggesting a positive modulation of the body's inflammatory response by DHA and EPA.
Overall, our investigation highlights a potential rapid benefit of using n-3 fatty acids, particularly DHA, in treating acute psoriasis. This indicates a promising avenue for improving the lives of those affected by this challenging skin condition.
Read More
Most Useful Reviews
9
Nutritional support
Omega-3 polyunsaturated fatty acids (PUFAs) are increasingly recognised for psoriasis. They not only aid in medication but also provide essential nutritional support. DHA and EPA in Omega-3 help stabilise immune functions, leading to reduced inflammation and fewer relapses in psoriasis.
Read More
7.5
Helpful for psoriasis
I have psoriasis, and during my last flare-up, my dermatologist advised me to regularly take Omega. It's a beneficial supplement! My husband and I take it together, and I've even ordered it for my parents.
Read More
Medical Researches
SCIENTIFIC SCORE
Possibly Effective
Based on 26 Researches
7.2
- All Researches
9.5
We evaluated the impact of docosahexaenoic acid (DHA) supplementation, alongside eicosapentaenoic acid (EPA), in patients suffering from chronic, stable psoriasis. This study involved 80 participants, 34 of whom also had psoriatic arthritis, and they were given specific doses of fatty acid ethyl esters for a period of eight weeks.
The results showed a noteworthy decrease in the Psoriasis Area Severity Index (PASI) scores, which went from an average of 3.56 before treatment to 1.24 after eight weeks. This significant reduction illustrates the potential effectiveness of DHA for managing symptoms of psoriasis, such as itching and plaque scaling.
It was particularly encouraging to see that seven patients were completely healed, with many others experiencing significant improvement. The majority of those with psoriatic arthritis reported feeling less joint pain during the study. Through our observations, it became clear that polyunsaturated ethyl ester lipids, like DHA, may serve as a valuable complement to traditional therapies for both psoriasis and psoriatic arthritis.
The results showed a noteworthy decrease in the Psoriasis Area Severity Index (PASI) scores, which went from an average of 3.56 before treatment to 1.24 after eight weeks. This significant reduction illustrates the potential effectiveness of DHA for managing symptoms of psoriasis, such as itching and plaque scaling.
It was particularly encouraging to see that seven patients were completely healed, with many others experiencing significant improvement. The majority of those with psoriatic arthritis reported feeling less joint pain during the study. Through our observations, it became clear that polyunsaturated ethyl ester lipids, like DHA, may serve as a valuable complement to traditional therapies for both psoriasis and psoriatic arthritis.
Read More
9
Eicosapentaenoic acid benefits psoriasis
We assessed the effects of eicosapentaenoic acid (EPA), an omega-3 fatty acid, on psoriasis through intravenous administration in a series of studies. The investigation aimed to understand whether replacing arachidonic acid, which has pro-inflammatory properties, with EPA could be beneficial for patients suffering from psoriasis.
Participants received daily infusions of either an EPA-based lipid emulsion or a conventional n-6 lipid emulsion. Throughout the studies, we closely monitored the clinical progression of psoriasis, along with specific inflammatory markers in the blood.
Our findings were notable: the group receiving the n-3 fatty acid treatment showed a significantly higher response rate. We observed a remarkable tenfold increase in specific products derived from neutrophils, indicating enhanced benefits from EPA. Additionally, plasma levels of EPA rose swiftly within just a few days of treatment.
In summary, our research suggests that intravenous administration of n-3 fatty acids effectively reduces psoriasis symptoms, likely due to alterations in inflammatory processes. This rapid response contrasts sharply with slower improvements seen with oral supplementation of fatty acids.
Participants received daily infusions of either an EPA-based lipid emulsion or a conventional n-6 lipid emulsion. Throughout the studies, we closely monitored the clinical progression of psoriasis, along with specific inflammatory markers in the blood.
Our findings were notable: the group receiving the n-3 fatty acid treatment showed a significantly higher response rate. We observed a remarkable tenfold increase in specific products derived from neutrophils, indicating enhanced benefits from EPA. Additionally, plasma levels of EPA rose swiftly within just a few days of treatment.
In summary, our research suggests that intravenous administration of n-3 fatty acids effectively reduces psoriasis symptoms, likely due to alterations in inflammatory processes. This rapid response contrasts sharply with slower improvements seen with oral supplementation of fatty acids.
Read More
We explored the effectiveness of a specialized treatment regimen involving docosahexaenoic acid (DHA) as part of an n-3 fatty acid lipid infusion for patients suffering from acute guttate psoriasis. This study included twenty hospitalized individuals with significant skin involvement and was conducted in a randomized, double-blind, placebo-controlled manner to ensure reliable results.
Participants received either a daily infusion of the n-3 fatty acid emulsion, which contained DHA and eicosapentaenoic acid (EPA), or a conventional n-6 lipid emulsion lacking significant benefits from omega-3s. We recorded clinical changes over ten days, assessing factors such as skin redness, swelling, and peeling, along with patients' subjective feelings about their symptoms.
The results were telling: those receiving the n-3 infusion showed a remarkable improvement in their psoriasis symptoms—between 45% and 76%—within just ten days. In contrast, the n-6 group experienced only moderate improvement, around 16-25%. Furthermore, we noted significant changes in the patients' immune response. The n-3 group had an increased production of beneficial leukotriene products, while inflammatory markers decreased, suggesting a positive modulation of the body's inflammatory response by DHA and EPA.
Overall, our investigation highlights a potential rapid benefit of using n-3 fatty acids, particularly DHA, in treating acute psoriasis. This indicates a promising avenue for improving the lives of those affected by this challenging skin condition.
Participants received either a daily infusion of the n-3 fatty acid emulsion, which contained DHA and eicosapentaenoic acid (EPA), or a conventional n-6 lipid emulsion lacking significant benefits from omega-3s. We recorded clinical changes over ten days, assessing factors such as skin redness, swelling, and peeling, along with patients' subjective feelings about their symptoms.
The results were telling: those receiving the n-3 infusion showed a remarkable improvement in their psoriasis symptoms—between 45% and 76%—within just ten days. In contrast, the n-6 group experienced only moderate improvement, around 16-25%. Furthermore, we noted significant changes in the patients' immune response. The n-3 group had an increased production of beneficial leukotriene products, while inflammatory markers decreased, suggesting a positive modulation of the body's inflammatory response by DHA and EPA.
Overall, our investigation highlights a potential rapid benefit of using n-3 fatty acids, particularly DHA, in treating acute psoriasis. This indicates a promising avenue for improving the lives of those affected by this challenging skin condition.
Read More
9
We explored how docosahexaenoic acid (DHA)—a key component of fish oil—could have a positive impact on psoriasis, a skin condition known for its inflammation and excessive skin cell growth. The study focused on how DHA is metabolized in guinea pig skin and its potential to influence inflammatory processes associated with this condition.
During our research, we incubated guinea pig skin enzyme preparations with two types of fatty acids from fish oil, namely eicosapentaenoic acid and DHA. We found that these fatty acids get converted into specific metabolites that might help regulate unwanted inflammation. Notably, the metabolites 15-hydroxyeicosapentaenoic acid and 17-hydroxydocosahexaenoic acid emerged from this conversion and showed promise as inhibitors of an enzyme linked to the production of inflammatory compounds.
The findings indicated that these metabolites effectively inhibit the enzyme 5-lipoxygenase, which is responsible for producing LTB4—a molecule linked to the worsening of psoriasis. The inhibitory effects observed give us insight into a possible mechanism through which DHA from fish oil could help alleviate symptoms of this challenging skin disorder. This metabolic pathway opens up avenues for future research into the therapeutic potential of DHA for managing psoriasis and similar inflammatory conditions.
During our research, we incubated guinea pig skin enzyme preparations with two types of fatty acids from fish oil, namely eicosapentaenoic acid and DHA. We found that these fatty acids get converted into specific metabolites that might help regulate unwanted inflammation. Notably, the metabolites 15-hydroxyeicosapentaenoic acid and 17-hydroxydocosahexaenoic acid emerged from this conversion and showed promise as inhibitors of an enzyme linked to the production of inflammatory compounds.
The findings indicated that these metabolites effectively inhibit the enzyme 5-lipoxygenase, which is responsible for producing LTB4—a molecule linked to the worsening of psoriasis. The inhibitory effects observed give us insight into a possible mechanism through which DHA from fish oil could help alleviate symptoms of this challenging skin disorder. This metabolic pathway opens up avenues for future research into the therapeutic potential of DHA for managing psoriasis and similar inflammatory conditions.
Read More
8
We aimed to understand how eicosapentaenoic acid (EPA) affects psoriasis, a skin condition known for causing redness, irritation, and thickened skin. By creating skin models that reflect both healthy and psoriatic conditions, we were able to assess the impact of EPA directly on lipid profiles—a key factor in skin health.
Our research revealed that in psoriatic skin models, there was a notable increase in certain fatty acids linked to inflammation, such as arachidonic acid (AA) and linoleic acid (LA). However, when we supplemented the media with EPA, we noticed a significant shift. The levels of beneficial omega-3 fatty acids, including EPA, docosahexaenoic acid (DHA), and docosapentaenoic acid (DPA), rose in both epidermal and dermal tissues.
More importantly, the addition of EPA helped to balance the production of lipid mediators in the skin. We observed increases in several anti-inflammatory molecules, such as prostaglandin E (PGE) and 12-hydroxyeicosapentaenoic acid (12-HEPE), indicating a move toward a more stable and healthier skin environment. These results suggest that EPA could play an important role in managing psoriasis by promoting a healthier lipid balance in the skin, potentially easing symptoms and encouraging skin healing.
Our research revealed that in psoriatic skin models, there was a notable increase in certain fatty acids linked to inflammation, such as arachidonic acid (AA) and linoleic acid (LA). However, when we supplemented the media with EPA, we noticed a significant shift. The levels of beneficial omega-3 fatty acids, including EPA, docosahexaenoic acid (DHA), and docosapentaenoic acid (DPA), rose in both epidermal and dermal tissues.
More importantly, the addition of EPA helped to balance the production of lipid mediators in the skin. We observed increases in several anti-inflammatory molecules, such as prostaglandin E (PGE) and 12-hydroxyeicosapentaenoic acid (12-HEPE), indicating a move toward a more stable and healthier skin environment. These results suggest that EPA could play an important role in managing psoriasis by promoting a healthier lipid balance in the skin, potentially easing symptoms and encouraging skin healing.
Read More
User Reviews
USERS' SCORE
Good
Based on 2 Reviews
8.5
- All Reviews
- Positive Reviews
- Negative Reviews
9
Nutritional support
Omega-3 polyunsaturated fatty acids (PUFAs) are increasingly recognised for psoriasis. They not only aid in medication but also provide essential nutritional support. DHA and EPA in Omega-3 help stabilise immune functions, leading to reduced inflammation and fewer relapses in psoriasis.
Read More
7.5
Helpful for psoriasis
I have psoriasis, and during my last flare-up, my dermatologist advised me to regularly take Omega. It's a beneficial supplement! My husband and I take it together, and I've even ordered it for my parents.
Read More
Frequently Asked Questions
No FAQs are available for this product and symptom.
References
- Morin S, Tremblay A, Dumais E, Julien P, Flamand N, et al. Eicosapentaenoic Acid Influences the Lipid Profile of an In Vitro Psoriatic Skin Model Produced with T Cells. Biomolecules. 2023;13. doi:10.3390/biom13091413
- Petrovic A, Bueide I, Tveit KS, Hallaråker H, Bjørndal B, et al. Herring roe oil in treatment of psoriasis - influence on immune cells and cytokine network. Front Immunol. 2023;14:1128986. doi:10.3389/fimmu.2023.1128986
- Vijayapoopathi S, Ramamoorthy R, Meganathan J, Kalaiyazhagan A, Bhuvarahamurthy S, et al. Nutraceutical combination ameliorates imiquimod-induced psoriasis in mice. Chem Biol Drug Des. 2023;102:1578. doi:10.1111/cbdd.14350
- Morin S, Bélanger S, Cortez Ghio S, Pouliot R. Eicosapentaenoic acid reduces the proportion of IL-17A-producing T cells in a 3D psoriatic skin model. J Lipid Res. 2023;64:100428. doi:10.1016/j.jlr.2023.100428
- Sorokin AV, Arnardottir H, Svirydava M, Ng Q, Baumer Y, et al. Comparison of the dietary omega-3 fatty acids impact on murine psoriasis-like skin inflammation and associated lipid dysfunction. J Nutr Biochem. 2023;117:109348. doi:10.1016/j.jnutbio.2023.109348
- Morin S, Simard M, Rioux G, Julien P, Pouliot R. Alpha-Linolenic Acid Modulates T Cell Incorporation in a 3D Tissue-Engineered Psoriatic Skin Model. Cells. 2022;11. doi:10.3390/cells11091513
- Zhan J, Tang X, Wang F, Han J. Association Between Daily Dietary Eicosatetraenoic Acid Intake and the Lower Risk of Psoriasis in American Adults. Clin Cosmet Investig Dermatol. 2021;14:1541. doi:10.2147/CCID.S333288
- Morin S, Simard M, Flamand N, Pouliot R. Biological action of docosahexaenoic acid in a 3D tissue-engineered psoriatic skin model: Focus on the PPAR signaling pathway. Biochim Biophys Acta Mol Cell Biol Lipids. 2021;1866:159032. doi:10.1016/j.bbalip.2021.159032
- Simard M, Rioux G, Morin S, Martin C, Guérin SL, et al. Investigation of Omega-3 Polyunsaturated Fatty Acid Biological Activity in a Tissue-Engineered Skin Model Involving Psoriatic Cells. J Invest Dermatol. 2021;141:2391. doi:10.1016/j.jid.2021.02.755
- Maruani A, Samimi M, Stembridge N, Abdel Hay R, Tavernier E, et al. Non-antistreptococcal interventions for acute guttate psoriasis or an acute guttate flare of chronic psoriasis. Cochrane Database Syst Rev. 2019;4:CD011541. doi:10.1002/14651858.CD011541.pub2
- Zulfakar MH, Edwards M, Heard CM. Is there a role for topically delivered eicosapentaenoic acid in the treatment of psoriasis?. Eur J Dermatol. 2007;17:284.
- Wolters M. [The significance of diet and associated factors in psoriasis]. Hautarzt. 2006;57:999.
- Gil A. Polyunsaturated fatty acids and inflammatory diseases. Biomed Pharmacother. 2002;56:388.
- Mayser P, Grimm H, Grimminger F. n-3 fatty acids in psoriasis. Br J Nutr. 2002;87 Suppl 1:S77.
- Danno K, Sugie N. Combination therapy with low-dose etretinate and eicosapentaenoic acid for psoriasis vulgaris. J Dermatol. 1998;25:703.
- Mayser P, Mrowietz U, Arenberger P, Bartak P, Buchvald J, et al. Omega-3 fatty acid-based lipid infusion in patients with chronic plaque psoriasis: results of a double-blind, randomized, placebo-controlled, multicenter trial. J Am Acad Dermatol. 1998;38:539.
- Saito-Sasaki N, Sawada Y, Mashima E, Yamaguchi T, Ohmori S, et al. Maresin-1 suppresses imiquimod-induced skin inflammation by regulating IL-23 receptor expression. Sci Rep. 2018;8:5522. doi:10.1038/s41598-018-23623-9
- Karrys A, Rady I, Chamcheu RN, Sabir MS, Mallick S, et al. Bioactive Dietary VDR Ligands Regulate Genes Encoding Biomarkers of Skin Repair That Are Associated with Risk for Psoriasis. Nutrients. 2018;10. doi:10.3390/nu10020174
- Xu J, Duan X, Hu F, Poorun D, Liu X, et al. Resolvin D1 attenuates imiquimod-induced mice psoriasiform dermatitis through MAPKs and NF-κB pathways. J Dermatol Sci. 2018;89:127. doi:10.1016/j.jdermsci.2017.10.016
- Mori TA, Beilin LJ. Omega-3 fatty acids and inflammation. Curr Atheroscler Rep. 2004;6:461.
- Søyland E, Lea T, Sandstad B, Drevon A. Dietary supplementation with very long-chain n-3 fatty acids in man decreases expression of the interleukin-2 receptor (CD25) on mitogen-stimulated lymphocytes from patients with inflammatory skin diseases. Eur J Clin Invest. 1994;24:236.
- Grimminger F, Mayser P, Papavassilis C, Thomas M, Schlotzer E, et al. A double-blind, randomized, placebo-controlled trial of n-3 fatty acid based lipid infusion in acute, extended guttate psoriasis. Rapid improvement of clinical manifestations and changes in neutrophil leukotriene profile. Clin Investig. 1993;71:634.
- Simopoulos AP. Omega-3 fatty acids in health and disease and in growth and development. Am J Clin Nutr. 1991;54:438.
- Lassus A, Dahlgren AL, Halpern MJ, Santalahti J, Happonen HP. Effects of dietary supplementation with polyunsaturated ethyl ester lipids (Angiosan) in patients with psoriasis and psoriatic arthritis. J Int Med Res. 1990;18:68.
- Miller C, Yamaguchi RY, Ziboh VA. Guinea pig epidermis generates putative anti-inflammatory metabolites from fish oil polyunsaturated fatty acids. Lipids. 1989;24:998.
- Stoof TJ, Korstanje MJ, Bilo HJ, Starink TM, Hulsmans RF, et al. Does fish oil protect renal function in cyclosporin-treated psoriasis patients?. J Intern Med. 1989;226:437.
